IL-22 receptor subunit alpha-1 (IL-22RA1)

Class

anti-IL-22RA1 monoclonal antibody

Pathway

IL-22 (and potentially IL-20/IL-24) signaling driving epidermal hyperplasia and barrier defects

Interleukin-22 receptor subunit alpha-1 (IL-22RA1) is the specificity-determining half of a receptor complex expressed mainly on epithelial cells of the skin, gut, and lung, rather than on immune cells. It pairs with a shared subunit, IL-10RB, to receive signals from interleukin-22 (IL-22), a cytokine produced by certain T helper cells and innate lymphoid cells. Because IL-22RA1 also participates in receptor complexes used by related cytokines in the IL-20 subfamily (including IL-20 and IL-24), blocking this receptor subunit can dampen signaling from more than one cytokine at once. In chronic inflammatory skin conditions, excessive IL-22 (and possibly IL-20/IL-24) signaling drives keratinocytes to proliferate abnormally, thickening the epidermis and disrupting the skin barrier. Antibodies directed against IL-22RA1 aim to interrupt this signaling at the receptor level, offering a way to reduce epidermal hyperplasia and restore more normal barrier function without directly neutralizing every cytokine individually. This approach is of interest in diseases where skin barrier dysfunction and epithelial overgrowth are central features, since it addresses a shared node in cytokine signaling rather than a single upstream driver. The broader relevance of this mechanism lies in conditions where epithelial tissues are chronically inflamed and remodeled, making receptor-level blockade a potentially efficient therapeutic strategy.